Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -74.91% is in line with its 5-year average of -70.00%, near the high end of its 5-year range (-242.84%–-15.24%).
48.28% below its 12-month average of -50.52%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -18.13%.
RETURN ON ASSETS (ROA)
-74.91%
RETURN ON ASSETS (ROA) AVG TTM
-50.52%
RETURN ON ASSETS (ROA) AVG 3Y
-40.48%
RETURN ON ASSETS (ROA) AVG 5Y
-70.00%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-48.28%
CURRENT VS 3Y AVG
-85.05%
CURRENT VS 5Y AVG
-7.01%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-28.29%
median of 524 covered companies
CURRENT VS SECTOR MEDIAN
-164.84%
vs the sector median at left
Acrivon Therapeutics, Inc. Common Stock
Market Cap
$85.60M
Return on Assets (ROA)
-74.91%
TTM Avg
-50.52%
3Y Avg
-40.48%
5Y Avg
-70.00%
Market Cap
$84.52M
Return on Assets (ROA)
-70.05%
TTM Avg
-71.47%
3Y Avg
-58.80%
5Y Avg
-51.13%
Market Cap
$84.44M
Return on Assets (ROA)
-43.13%
TTM Avg
-80.45%
3Y Avg
-58.18%
5Y Avg
-65.67%
Market Cap
$83.97M
Return on Assets (ROA)
-79.38%
TTM Avg
41.63%
3Y Avg
-36.06%
5Y Avg
-44.84%
Market Cap
$81.80M
Return on Assets (ROA)
49.88%
TTM Avg
-47.68%
3Y Avg
-37.92%
5Y Avg
-34.36%
Market Cap
$87.11M
Return on Assets (ROA)
8.52%
TTM Avg
11.64%
3Y Avg
-8.81%
5Y Avg
-6.61%
Market Cap
$89.11M
Return on Assets (ROA)
1.69%
TTM Avg
-3.62%
3Y Avg
-6.49%
5Y Avg
-4.78%
Market Cap
$88.84M
Return on Assets (ROA)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$89.78M
Return on Assets (ROA)
-30.70%
TTM Avg
-50.88%
3Y Avg
-51.94%
5Y Avg
-48.05%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Acrivon Therapeutics, Inc. Common Stock (ACRV) | $85.60M | -74.91% | -50.52% | -40.48% | -70.00% |
| Humacyte, Inc. (HUMA)vs › | $84.52M | -70.05% | -71.47% | -58.80% | -51.13% |
| Cognition Therapeutics, Inc. (CGTX)vs › | $84.44M | -43.13% | -80.45% | -58.18% | -65.67% |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $83.97M | -79.38% | 41.63% | -36.06% | -44.84% |
| LENSAR Inc (LNSR)vs › | $81.80M | 49.88% | -47.68% | -37.92% | -34.36% |
| CareCloud, Inc. (CCLD)vs › | $87.11M | 8.52% | 11.64% | -8.81% | -6.61% |
| ImmuCell Corporation (ICCC)vs › | $89.11M | 1.69% | -3.62% | -6.49% | -4.78% |
| Conexeu Sciences Inc. (CNXU)vs › | $88.84M | N/A | N/A | N/A | N/A |
| Equillium, Inc. (EQ)vs › | $89.78M | -30.70% | -50.88% | -51.94% | -48.05% |
| Cardiff Oncology, Inc. (CRDF)vs › | $88.63M | -107.29% | -60.42% | -51.23% | -39.69% |
ROA
-74.9%
ROE
-85.7%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -60.06% |
| 2024-12-31 | -40.98% |
| 2023-12-31 | -43.68% |
| 2022-12-31 | -17.20% |
| 2021-12-31 | -15.24% |
| 2020-12-31 | -242.84% |
